CD276 and neoplasm: GD2-B7H3 T cells were next tested in vivo in a metastatic NBL xenogeneic model in which infusion of 1 × 107 GD2-B7H3 T cells (estimated based on the fraction of GD2 scFv × fraction of B7H3 scFv as detected by flow cytometry) on day 7 post-tumor inoculation led to complete cure.